Predictive value of post‐treatment C‐reactive protein‐to‐albumin ratio in locally advanced non–small cell lung cancer patients receiving durvalumab after chemoradiotherapy

BACKGROUNDS: The PACIFIC trial established durvalumab consolidation therapy after concurrent chemoradiotherapy (CCRT) as the standard treatment for locally advanced non–small cell lung cancer (LA‐NSCLC). However, little is known about the predictive factors of durvalumab efficacy in this population....

Descripción completa

Detalles Bibliográficos
Autores principales: Araki, Taisuke, Tateishi, Kazunari, Komatsu, Masamichi, Sonehara, Kei, Wasamoto, Satoshi, Koyama, Shigeru, Yoshiike, Fumiaki, Hama, Mineyuki, Nishie, Kenichi, Kondo, Daichi, Agatsuma, Toshihiko, Kato, Akane, Takata, Munetake, Kanda, Shintaro, Hanaoka, Masayuki, Koizumi, Tomonobu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9284133/
https://www.ncbi.nlm.nih.gov/pubmed/35616056
http://dx.doi.org/10.1111/1759-7714.14484

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9284133/
https://www.ncbi.nlm.nih.gov/pubmed/35616056
http://dx.doi.org/10.1111/1759-7714.14484

Ejemplares similares